Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2005-02-15
2005-02-15
Dentz, Bernard (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C546S118000
Reexamination Certificate
active
06855723
ABSTRACT:
The present invention is directed in part towards methods of modulating the function of serine/threonine protein kinases with azabenzimidazole-based compounds. The methods incorporate cells that express a serine/threonine protein kinase, such as RAF. In addition, the invention describes methods of preventing and treating serine/threonine protein kinase-related abnormal conditions in organisms with a compound identified by the invention. Furthermore, the invention pertains to azabenzimidazole compounds and pharmaceutical compositions comprising these compounds.
REFERENCES:
patent: 3590045 (1971-06-01), Vogt et al.
patent: 4144341 (1979-03-01), Clark et al.
patent: 4247556 (1981-01-01), Von Bebenburg et al.
patent: 5217999 (1993-06-01), Levitzki et al.
patent: 5302606 (1994-04-01), Spada et al.
patent: 5330992 (1994-07-01), Eissenstat et al.
patent: 5582995 (1996-12-01), Avruch et al.
patent: 2241575 (1972-08-01), None
patent: 0 566 226 (1993-10-01), None
patent: 198716 (1989-11-01), None
patent: WO91/15495 (1991-10-01), None
patent: WO92/20642 (1992-11-01), None
patent: WO92/21660 (1992-12-01), None
patent: WO94/14808 (1994-07-01), None
patent: WO94/03427 (1996-08-01), None
patent: WO96/22976 (1996-08-01), None
patent: WO96/40116 (1996-12-01), None
Bonner et al., “Structure and Biological Activity of HumanHomologs of the raf/mil Oncogene.”. Molecular and Cellular Biology 5:1400-1407 (1985).
Folkman. “What is the Evidence that Tumors are Angiogenesis Dependent?” Journal of the National Cancer Institute 82:4-6 (1990).
Monia et al., “Antitumor activity of a phosphorothioate antisense oligodeoxynucleotide targeted against C-raf kinase,” Nature Medicine 2:668-675 (1996).
Morrison et al., “Signal Transduction from Membrane to Cytoplasm: Growth Factors and Membrane-Bound Oncogene Products Increase Raf-1 Phosphorylation and Associated Protein Kinase Activity,” Proc. Natl. Acad. Sci. USA 85:8855-8859 (1988).
Robbins et al , “Regulation and properties of extracellular signal-regulated protein kinases 1 and 2 in vitro,” J. Biol. Chem. 268:5097-5106 (1993).
Chem. Abstracts. 93:95098. Von Bebenburg et al., Chem.-Ztg., 103(12) p. 387-389. 1979.
Chem Abstracts, 51.10518. Dornow et al., Arch. Pharm., 290. p. 20-31, 1957.
Russian Examination Report.
Hungarian Search Report.
App Harald
Kutscher Bernhard
McMahon Gerald
Weinberger Heinz
Dentz Bernard
Pillsbury & Winthrop LLP
Zentaris GmbH
LandOfFree
Methods of modulating serine/threonine protein kinase... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods of modulating serine/threonine protein kinase..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods of modulating serine/threonine protein kinase... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3501139